Invasive Aspergillus infection of middle ear in a patient treated with secukinumab, methotrexate, and corticosteroids for psoriasis and psoriatic arthritis-Reference-Cited by-同舟云学术

Invasive Aspergillus infection of middle ear in a patient treated with secukinumab, methotrexate, and corticosteroids for psoriasis and psoriatic arthritis

Published:2022-07-26 Issue:7 Volume:33 Page:3063-3065
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Rob Filip¹,Školoudík Lukáš²,Chrobok Viktor²,Dědková Jana³,Kašparová Petra⁴,Podrazilová Lucie⁵

Affiliation:

1. Department of Dermatovenereology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague, Czech Republic

2. Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic

3. Department of Radiology, University Hospital Hradec Králové, Hradec Králové, Czech Republic

4. The Fingerland Department of Pathology, University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic

5. Department of Rheumatology, Revma Praha, Prague, Czech Republic

Funder

Cooperation Program

Czech Health Research Council

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2022.2104442

Reference8 articles.

1. The IL-17 Family of Cytokines in Health and Disease

2. IL-17 Blockade in Psoriasis

3. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

4. IL-17–Mediated Immunity to the Opportunistic Fungal PathogenCandida albicans

5. Aspergillosis in patients treated with monoclonal antibodies

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppressants;Reactions Weekly;2022-08-20